Advertisement
Canada markets close in 5 hours 48 minutes

  • S&P/TSX

    21,980.69
    -31.03 (-0.14%)
     

  • S&P 500

    5,082.35
    +11.80 (+0.23%)
     

  • DOW

    38,510.27
    +6.58 (+0.02%)
     

  • CAD/USD

    0.7296
    -0.0024 (-0.33%)
     

  • CRUDE OIL

    82.89
    -0.47 (-0.56%)
     

  • Bitcoin CAD

    90,619.95
    -747.89 (-0.82%)
     

  • CMC Crypto 200

    1,427.21
    +3.11 (+0.22%)
     

  • GOLD FUTURES

    2,334.00
    -8.10 (-0.35%)
     

  • RUSSELL 2000

    2,003.74
    +1.09 (+0.05%)
     

  • 10-Yr Bond

    4.6480
    +0.0500 (+1.09%)
     

  • NASDAQ

    15,799.73
    +103.09 (+0.66%)
     

  • VOLATILITY

    15.80
    +0.11 (+0.70%)
     

  • FTSE

    8,060.61
    +15.80 (+0.20%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6818
    -0.0018 (-0.26%)
     
MARKETS LIVE BLOG:

STOCKS OPEN MIXED, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

Is AbbVie a Bad News Buy?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·4 min read

The U.S. Food and Drug Administration recently announced restrictions on JAK inhibitors that hurt AbbVie's (NYSE: ABBV) prospects for autoimmune disease drug Rinvoq. AbbVie stock sank more than 10% after the FDA's decision. In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie stock is now a bad news buy.

Continue reading